| Budget Amount *help |
¥17,030,000 (Direct Cost: ¥13,100,000、Indirect Cost: ¥3,930,000)
Fiscal Year 2014: ¥5,460,000 (Direct Cost: ¥4,200,000、Indirect Cost: ¥1,260,000)
Fiscal Year 2013: ¥5,330,000 (Direct Cost: ¥4,100,000、Indirect Cost: ¥1,230,000)
Fiscal Year 2012: ¥6,240,000 (Direct Cost: ¥4,800,000、Indirect Cost: ¥1,440,000)
|
|---|
| Outline of Final Research Achievements |
Genetic polymorphisms of drug-metabolizing enzymes are relevant to interindividual differences in pharmacokinetics, drug response and toxicity. Effects of SNPs in the coding region and 5’-UTR on enzyme activities or expression levels have been well studied, whereas SNPs in the 3’-UTR have been overlooked. Some SNPs in the 3’-UTR of concerned genes are associated with the change in the expression level. In this study, we found that human CYP2E1, AKR1D1, and TYMS are regulated by microRNA in the genotype-dependent manner. This is the first proof that a SNP(s) in the 3’-UTR of drug-metabolizing enzymes affects binding of miRNA to modulate the expression in the liver.
|
